• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Urology >Prostate cancer: Enzalutamide PREVAILs
【24h】

Prostate cancer: Enzalutamide PREVAILs

机译：前列腺癌：恩杂鲁胺

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Interim analysis of the PREVAIL trial, demonstrating the superiority of enzalutamide over placebo for patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), has now been published in The New England Journal of Medicine. The study data demonstrate that enzalutamide not only significantly improves survival outcomes, but also delays the need for chemotherapy, reduces serum PSA levels and is associated with better health-related quality of life. This won t be the first you've heard of PREVAIL (NCT0121299), the double-blind phase III randomized controlled trial of enzalutamide versus placebo in the prechemotherapy setting that was halted early owing to overwhelming response to treatment. 1,717 men with mCRPC who had not previously received chemotherapy were recruited at 207 sites around the world between September 2010 and September 2012. Patients were randomized to receive a daily dose of either enzalutamide (n = 872) or placebo (ft = 845). Co-primary end points were overall survival and radiographic progression-free survival.
机译：PREVAIL试验的中期分析表明，对于未接受过化学治疗的转移性去势抵抗性前列腺癌（mCRPC）患者，enzalutamide优于安慰剂，现已发表在《新英格兰医学杂志》上。研究数据表明，enzalutamide不仅显着改善了生存结果，而且延迟了化疗的需要，降低了血清PSA水平，并且与健康相关的生活质量更高。这将不会是您第一次听说PREVAIL（NCT0121299），这是enzalutamide与安慰剂在化学治疗前的双盲III期随机对照试验，由于对治疗的反应异常，该研究被中止了。在2010年9月至2012年9月期间，在全球207个地点招募了1,717名先前未接受过化疗的mCRPC男性。患者被随机分配接受每日剂量的恩杂鲁胺（n = 872）或安慰剂（ft = 845）。共同主要终点为总体生存期和无影像学进展生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号